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ABSTRACT
Aims To demonstrate the potential use of in vitro poly
(lactic-co-glycolic acid) (PLGA) microparticles in
comparison with triamcinolone suspension to aid
visualisation of vitreous during anterior and posterior
vitrectomy.
Methods PLGA microparticles (diameter 10e60 mm)
were fabricated using single and/or double emulsion
technique(s) and used untreated or following the surface
adsorption of a protein (transglutaminase). Particle size,
shape, morphology and surface topography were
assessed using scanning electron microscopy (SEM) and
compared with a standard triamcinolone suspension. The
efficacy of these microparticles to enhance visualisation
of vitreous against the triamcinolone suspension was
assessed using an in vitro set-up exploiting porcine
vitreous.
Results Unmodified PLGA microparticles failed to
adequately adhere to porcine vitreous and were readily
washed out by irrigation. In contrast, modified
transglutaminase-coated PLGA microparticles
demonstrated a significant improvement in adhesiveness
and were comparable to a triamcinolone suspension in
their ability to enhance the visualisation of vitreous. This
adhesive behaviour also demonstrated selectivity by not
binding to the corneal endothelium.
Conclusion The use of transglutaminase-modified
biodegradable PLGA microparticles represents a novel
method of visualising vitreous and aiding vitrectomy. This
method may provide a distinct alternative for the
visualisation of vitreous whilst eliminating the
pharmacological effects of triamcinolone acetonide
suspension.
INTRODUCTION
Posterior capsule rupture resulting in vitreous
prolapse is a common complication during cataract
extraction. The incidence of posterior capsule
rupture after phacoemulsiﬁcation ranges from
1.41% to 5.1%.1 A thorough anterior vitrectomy
must be performed to reduce the incidence of
complications such as elevated intraocular pressure,
cystoid macular oedema, retinal detachment,
eccentric pupil and endophthalmitis.2 The
surgeons’ ability to undertake an adequate anterior
vitrectomy is often made difﬁcult by the inability
to adequately visualise vitreous in the anterior
chamber under a surgical microscope and, for this
reason, a substance is needed to enhance the visu-
alisation of the vitreous.
Triamcinolone acetonide, a particulate steroid
suspension, has been successfully utilised in visu-
alising vitreous during anterior vitrectomy.3 4 It is
rinsed and diluted 1:10 prior to use.3 Nevertheless,
animal studies have shown the potential for
endothelial damage and toxicity with its use.5 6
Moreover, the use of triamcinolone within the
anterior chamber predisposes the eye to undesired
and uncontrolled intraocular delivery of a steroid.
As such, there is a risk of elevated post-operative
intraocular pressure and steroid-induced glaucoma,
even though removal of the agent is attempted at
the time of surgery.7 8
More recently dyes and particulate substances
have been proposed as an alternative to the use of
triamcinolone.7e12 However, no extensive long-
term experimental studies on the safety of these
stains as intraocular dyes have been performed and
there are conﬂicting reports on their safety.7 11 12
Poly(lactic-co-glycolic acid) (PLGA) is a biodegrad-
able polymer that is used extensively in biomedical
applications, including in the eye.13 In addition,
growth factor- and/or drug-incorporated PLGA
microparticles have also been exploited as drug
delivery vehicles to the posterior segment with in
vivo rabbit studies demonstrating the biocompati-
bility of intravitreally administered PLGA micro-
particles.14e16 Furthermore, PLGA can be
extensively modiﬁed by various modalities that can
render it more hydrophilic and enhance its
biocompatibility.17
In this present study, we demonstrate the effec-
tiveness, in vitro, of surface-modiﬁed PLGA micro-
particles inallowingadequatevisualisationofvitreous.
MATERIALS AND METHODS
Manufacture of PLGA microparticles
PLGA (PLGA 85:15 DL; High IV; molecular weight
118 kDa) (Lakeshore Biomaterials, Birmingham,
Alabama, USA) microparticles were fabricated
using a single oil-in-water (O/W) emulsion tech-
nique as previously described.18 Brieﬂy, 1.0 g of
PLGA polymer was dissolved in 5 ml dichloro-
methane (DCM) (Fisher Scientiﬁc, Loughborough,
UK) overnight at room temperature in a glass
scintillation phial. Five millilitres of 0.3% (weight/
volume) poly(vinyl alcohol) (PVA; molecular
weight 13 000e23 000 kDa; 87e89% hydrolysed)
(Sigma-Aldrich, Poole, UK) was then slowly added
to the phial before the solution was emulsiﬁed
using a Chiltern Scientiﬁc VM20 vortex mixer, scale
5 setting, for 45 s (Chiltern Scientiﬁc Instruments,
Wendover, UK). This primary O/W emulsion was
poured into a 0.3% (weight/volume) PVA solution
water-bath and stirred constantly overnight to
allow the solvent to evaporate. Microparticles were
then sieved and separated using a Retsch AS200
sieve shaker (Retsch UK Ltd, Leeds, UK).
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Oil-Red-O (Red O dye (Solvent Red 27; (1-([4-(xylylazo)xylyl]
azo)-2-naphthol)) and/or Fast-Green-FCF (both from Sigma-
Aldrich) were incorporated into the microparticles using the
aforementioned O/W single emulsion technique. One hundred
microlitres of the dye was thoroughly mixed with the 5 ml
PLGA/DCM solution to form the primary emulsion and
processed as described above.
Size profiling and distribution
The size distribution of the pre-fractionated microparticles was
determined by laser diffraction. Samples were dispersed in 4 ml
of distilled water within the chamber of a Coulter LS230 particle
size analyser (Beckman Coulter, High Wycombe, UK) under
moderate stirring (default speed 3 setting) to the required
concentration as indicated by the in-built display software.
Particle size ranges were deﬁned using PSS-Duke standards
(Polymer Standard Service, Kromatek Ltd, Dunmow, UK).
Particle size distribution was then determined as a function of the
particle diffraction using the Coulter software (version 2.11a) and
plotted as a function of the percentage of distribution volume.
Transglutaminase isolation and purification
The microbial transglutaminase (mTG; isolated from Strepto-
verticillium mobaraense) used throughout this investigation was
sourced from the commercially available product, Activa WM
(Ajinomoto Corporation Inc., Tokyo, Japan). Tissue trans-
glutaminase (mammalian transglutaminase; tTG) was isolated
and puriﬁed from guinea pig livers as previously described.19
Surface adsorption of proteins onto microparticles
Microparticles were pre-wetted with serum-free Dulbecco’s
modiﬁed Eagle’s medium (DMEM) for 24 h in a humidiﬁed-
atmosphere incubator at 378C and 5% (volume/volume) CO2 in
air prior before being coated with the appropriate protein/
enzyme (ie, bovine serum albumin (BSA) control, mTG or tTG)
using a standard surface adsorption protocol. Microparticles
(30 mg) were incubated overnight with 1 ml of either 1 mg/ml
BSA, mTG or tTG solution on a Stuart SRT6 roller mixer (VWR
International Ltd, Lutterworth, UK) (default settings) in
a humidiﬁed-atmosphere incubator at 378C, 5% (volume/
volume) CO2 in air. Following the coating procedure, samples
were washed once with 10 mmol/l EDTA and then with PBS,
pH 7.4, twice, before immediate use.
Samples exploiting the active-site directed inhibitor termed
‘R281’ (a synthetic carboxybenzoyl-glutaminyl-glycine analogue,
developed in-house) were used as negative controls to the cross-
linking activity of the enzyme (pre-treatment for 1 h, 500 mmol/l,
at 378C, followed by dialysis in phosphate buffered saline
(PBS), pH 7.4) as previously described.19 20 Non-crosslinking tTG
enzyme (ie, without the addition CaCl2) was also used as a
negative control for catalytic activity.
Visualisation of vitreous
The efﬁcacy of these microparticles to enhance the visualisation
of vitreous against triamcinolone suspension (triamcinolone
acetonide solution (Kenalog; 40 mg/ml) (ER Squibb and Sons
Ltd, Uxbridge, UK) was assessed using a simple in vitro set-up
exploiting porcine vitreous (Local abattoir, Nottingham, UK).
Cornea, iris and lens were dissected allowing adequate access to
the vitreous cavity. The vitreous was grasped using micro-
toothed forceps before being cut with Westcott scissors. The
vitreous was placed in 2 ml PBS, pH 7.4, in a 24 well plate.
Microparticles and/or triamcinolone suspension were then
added, using a Rycroft cannula, to the vitreous. Samples were
then transferred to adjacent PBS-ﬁlled wells using a Pasteur
pipette and thoroughly agitated. Consecutive washes were
performed using this method before samples were viewed using
a Leica MZ16F stereomicroscope and images captured using the
in-built camera.
RESULTS
The fabrication of PLGA microparticles
PLGA microparticles were fabricated using the single O/W
technique and analysed by SEM and stereomicroscopy for both
morphology and topography, as summarised in ﬁgure 1.
Microparticles manufactured using this technique were spherical
and possessed smooth surface characteristics with a typical size
distribution shown in ﬁgure 2. These microparticles could also
Figure 1 Scanning electron
microscope (SEM) and brightfield
microscopy images of triamcinolone
acetonide suspension and poly(lactic-co-
glycolic acid) (PLGA) microparticles.
Lyophilised triamcinolone solution and
20e100 mm PLGA microparticles were
mounted on aluminium SEM stubs, gold-
coated under an argon atmosphere
before being imaged using a JOEL
6060LV variable pressure SEM operating
at an accelerating voltage of 10 kV at the
corresponding magnification (A, B and C,
D, respectively). Brightfield images of
1 mg/ml triamcinolone solution and
PLGA microparticles, in phosphate
buffered saline (PBS), were achieved
using a Leica DM-IRB/E inverted
microscope and captured using the
in-built imaging software (C and F,
respectively).
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be further fractionated within the 10e60 mm size range, which
was comparable to the particulate size found in the triamcino-
lone acetonide suspension (<50 mm). Moreover, on comparison
to the triamcinolone acetonide suspension, which demonstrated
a random-sized particulate mixture, these microparticles were
fabricated with consistent pre-deﬁned parameters and associated
characteristics (ie, uniform shape, size and surface topography
within a deﬁned distribution). The successful incorporation of
‘molecules-of-interest’ was also demonstrated by the incorpo-
ration of selective dye reagents (ie, Oil-Red-O and Fast-Green-
FCF). In addition, further modiﬁcation of these microparticles
was achieved via the surface adsorption of proteins, namely TG
or BSA.
Enhancing visualisation of vitreous
Sample vitreous, once wetted, is extremely difﬁcult to visualise,
as seen in ﬁgure 3A. In contrast, following the addition of
triamcinolone acetonide, the vitreous becomes more obvious and
easier to identify in solution (ie, irrigation wash during typical
ophthalmic surgery) as demonstrated in ﬁgure 3B. Even after
washing in PBS, the vitreous exposed to triamcinolone can still
be visualised. Control PLGA microparticles (ie, not surface
modiﬁed), coloured red via the incorporation of Oil-Red-O dye
to aid visualisation during manipulation in these experiments,
demonstrated no adhesion to the vitreous and were almost
completely removed following consecutive washes with PBS
(ﬁgure 4A). In comparison, PLGA microparticles treated by the
surface adsorption of mTG (PLGAemTGeMP), demonstrated
a signiﬁcant increase and ability to adhere to the vitreous and
maintained complete adhesion even following extensive
consecutive washing steps (ﬁgure 4B,C). On comparing
a normalised quantity (weight for weight in a ﬁxed volume) of
triamcinolone acetonide and PLGA microparticles, it can be seen
that the enhanced visualisation effect of the microparticles was
comparable to the triamcinolone suspension (comparing ﬁgure
4C with ﬁgure 3B). Control microparticles that were pre-
treated/surface adsorbed with BSA (PLGAeBSAeMP) demon-
strated no adhesive properties at all and appeared to be unable to
localise around the vitreous during the addition step. PLGA-BSA-
MPs were almost completely removed during the initial washing
step with PBS (ﬁgure 5A). Veriﬁcation of the adhesive nature
Figure 2 Size distribution of fabricated poly(lactic-co-glycolic acid)
(PLGA) microparticles. Microparticles were dispersed in 4 ml of distilled
water within the chamber of a Coulter LS230 particle size analyser under
moderate stirring. Particle size distribution was then determined as
a function of the particle diffraction using the Coulter software (version
2.11a) and plotted, as shown above, as a function of the percentage of
distribution volume.
Figure 3 Visualisation of vitreous using
triamcinolone solution. The comparative
visualisation of (A) control vitreous and
(B) triamcinolone acetonide-treated
vitreous were visualised using a Leica
MZ16F stereomicroscope immediately
following the addition of phosphate
buffered saline (PBS) or triamcinolone
(left) and following consecutive washes
with PBS solution (right). Images were
captured using the in-built software and
shown at 1.63 magnification.
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of the PLGAemTGeMPs was further investigated using the
R281-inhibited control samples of the mTG (ﬁgure 5B). A
similar behaviour was observed using the inactivated mamma-
lian form of the enzyme (ie, tTG without addition of CaCl2) as
seen in ﬁgure 5C.
Selective adhesiveness of PLGA microparticles
The adhesion of (Oil-Red-O incorporated) PLGAemTGeMP to
the sample vitreous was found to be stable even after several
extensive washing steps (more than seven washes with PBS).
However, the ability of these microparticles to adhere to other
tissues was found to be selective. PLGAeTGeMP was unable to
adhere to the corneal endothelium or iris and were completely
removed during the ﬁrst washing step (not shown) as would be
desired in surgical applications to minimise endothelial damage
or compromise.
DISCUSSION
Thorough removal of the vitreous is essential in cases of vitreous
prolapsed in to the anterior chamber during cataract surgery and
in retinal detachment and proliferative diabetic retinopathy
requiring pars plana vitrectomy (PPV). The vitreous, though
transparent in nature, may be visualised by light scatter such
that there is an increase in the angle between illumination and
viewing. In the setting of PPV, this can be achieved via the use of
a ﬁbre optic light pipe. However, the visualisation of the anterior
vitreous and vitreous base using co-axial illumination from an
operating microscope can be problematic.21 An agent that
permits visualisation of the vitreous is therefore required during
surgery and is of particular importance to ophthalmic surgeons
in training.9 The current, commonly used, method exploits
triamcinolone acetonide to aid the visualisation of vitreous
during such situations. However, not only do the tedious prep-
aration steps for triamcinolone limit its use during surgery, but
the direct addition and possibility of residual steroid localised
within the eye poses additional risks to the patient.3 Further-
more, in vivo models have also demonstrated endothelial
damage and toxicity following use of intracameral triamcino-
lone.5 6 Hence, in this study, we present a novel methodology of
visualising vitreous using microparticles fabricated from PLGA
with the aim of minimising the risk of introducing endogenous
steroid agents or the toxicity issues associated with certain
ophthalmological dyes.
The biodegradable polymer, PLGA, has been used extensively
for many tissue engineering and drug delivery applications. An
important feature of this polymer is that it gradually breaks down
within an aqueous environment and degrades into water-soluble,
non-toxic, by-products. These degradation products can then be
cleared by the body through metabolic pathways and hence are
eliminated from the implant site.22 In this investigation, we
Figure 5 Visualisation of vitreous
using modified poly(lactic-co-glycolic
acid) (PLGA) microparticles. The
comparative visualisation of vitreous
following incubation with (A) Fast-
Green-FCF incorporated bovine serum
albumin (BSA)-treated PLGA
microparticles and (B) Oil-Red-O
incorporated microbial
transglutaminase-treated PLGA
microparticles. Transglutaminase cross-
linking activity was inhibited with the
active-site directed inhibitor, R281, prior
to adsorption on the microparticle
surface. (C) Oil-Red-O incorporated
mammalian transglutaminase-treated
PLGA microparticles. Microparticles
used were in the 20e100-mm range and
samples visualised using a Leica MZ16F
stereomicroscope following the addition (left) and after consecutive washes (middle and right) of the microparticles with phosphate buffered saline
(PBS). Images were captured using the in-built software and shown at 1.63 magnification.
Figure 4 Visualisation of vitreous
using poly(lactic-co-glycolic acid)
(PLGA) microparticles. The comparative
visualisation of vitreous following
incubation with (A) untreated Oil-Red-O
incorporated PLGA microparticles,
(B) Oil-Red-O incorporated microbial
transglutaminase-treated PLGA
microparticles, (C) microbial
transglutaminase-treated PLGA
microparticles (no Oil-Red-O).
Microparticles used were in the
20e100 mm diameter range and
samples visualised using a Leica MZ16F
stereomicroscope immediately
following the addition (left) and after
two consecutive washes (middle and right) of the microparticles with phosphate buffered saline (PBS). Images were captured using the in-built
software and shown at 1.63 magnification.
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utilised the PLGA polymer in the form of microparticles solely as
a visualisation tool. However, these microparticles could to be
exploited in the future as a mode of targeted drug delivery.
Within this study, the characteristics (ie, particle shape and size)
of these fabricatedmicroparticleswere shown to be comparable to
the insoluble particulates found in the triamcinolone acetonide
suspension which, based on the integration of the crystals into
loosely organised collagenmatrices, allows the visualisation of the
vitreous.23However, in contrast, unmodiﬁed PLGAmicroparticles
were unable to sufﬁciently adhere to vitreous without prior
treatment, in this case, with the enzyme TG. TG, commonly
referred to as a ‘biological glue’, has been reported extensively to
act as a biocatalyst, to enhance cell adhesion, to promote surface
modiﬁcations and to increase the biocompatibility of many tissue
engineering scaffolds without inducing any signiﬁcant immune
response.24e28 Previous experiments have already demonstrated
the potential clinical use of TG as a novel cartilageecartilage
biological glue.29 As such, itwas hypothesised that the pre-surface
adsorption of the PLGAmicroparticleswithTGwould enhance its
adhesiveness and aid the visualisation of vitreous. Such a system
could be easily exploited during surgery.
This study showed that TG-treated microparticles do indeed
adhere to the vitreous in such a manner that is comparable to
triamcinolone acetonide suspension. Moreover, this adhesiveness
was shown to be selective and the microparticles would only
adhere to the vitreous and not to the other anterior chamber
structures (ie, the corneal endothelium and iris). It is hypoth-
esised that this behaviour may be based upon the ability of the
enzymes to bind to peptide sequences up to 12 residues long,
with collagen being a good substrate.19 30 31 Further conﬁrmation
of this effect being solely dependent on the pre-surface adsorp-
tion of the TG can be seen in comparison with BSA-treated
control microparticles. Above all, repeated washing of the
microparticles could not dislodge and/or facilitate their removal
from the vitreous and hence, they would be ideal for application
as a visualisation tool to aid the removal of prolapsed vitreous,
which otherwise is virtually invisible. In addition, similar and
corresponding effects between the microbial and mammalian
versions of the enzyme have been demonstrated. This means that
in vivo applications may be potentially considered with minimal
immunological response. In addition, the incorporation of selec-
tive dyes (eg, Oil-Red-O and Fast-Green-FCF) demonstrates the
possibility of entrapping anti-microbials/drugs and/or other
molecules of interest within these microparticles to facilitate and
enhance healing during or following surgery.32 Hence, the pres-
ence of any residual microparticles may not be a disadvantage
(compared with the presence of steroids or their precursors) but,
in fact, may be desired in speciﬁc applications.
CONCLUSIONS
Herein, we report a novel method of visualising vitreous and
aiding anterior vitrectomy by exploiting the use of biodegradable
PLGA microparticles. This method may provide a distinct
alternative to the use of triamcinolone acetonide suspension and
other common surgical dyes without the associated pharmaco-
logical and/or toxicity effects. However, extensive in vivo studies
are required to further investigate the efﬁcacy and safety proﬁle
of this novel system prior to potential human use.
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